Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression |
| |
| Authors: | Lisa?Sanderson?Cox,Christi?A.?Patten author-information" > author-information__contact u-icon-before" > mailto:patten.christi@mayo.edu" title=" patten.christi@mayo.edu" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Raymond?S.?Niaura,Paul?A.?Decker,Nancy?Rigotti,David?P.?L.?Sachs,A.?Sonia?Buist,Richard?D.?Hurt |
| |
| Affiliation: | Nicotine Dependence Center Research Program, Mayo Clinic, Rochester, Minnesota 55905, USA. |
| |
| Abstract: | BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression. |
| |
| Keywords: | smoking relapse prevention major depression bupropion therapy |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
